Parasite Cleanse
Take with Fenbendazole and Cholic Tudca
Script Required - Contact us if you need a script
 
Recommended Dosage:
12mg - 41kg to 59kg
15mg - 60kg to 77kg
18mg - 78kg to 95kg
22mg - 96kg to 113kg
 
Ivermectin is a broad-spectrum antiparasitic drug, primarily used to treat parasitic infections in humans and animals. It works by binding to glutamate-gated chloride channels in parasites, causing paralysis and death. Beyond its established role in parasitology, ivermectin has been investigated for off-label uses, particularly during the COVID-19 pandemic. 
 
Benefits of Ivermectin
1.  Effective Antiparasitic Treatment:
    •  Onchocerciasis (River Blindness): Ivermectin is a cornerstone treatment for onchocerciasis, caused by Onchocerca volvulus, reducing microfilarial loads and preventing blindness. It’s administered annually or biannually (e.g., 150–200 µg/kg) in mass drug administration programs.
    •  Lymphatic Filariasis: Used in combination with albendazole to eliminate Wuchereria bancrofti, reducing transmission and disease burden.
    •  Strongyloidiasis: Highly effective against Strongyloides stercoralis, curing intestinal infections and preventing severe hyperinfection in immunocompromised patients (e.g., 200 µg/kg for 1–2 days).
    •  Scabies and Head Lice: Treats scabies (Sarcoptes scabiei) and pediculosis with oral (200 µg/kg, 1–2 doses) or topical formulations, offering an alternative to permethrin.
    •  Other Parasites: Effective against roundworms (Ascaris lumbricoides), whipworms, and certain ectoparasites, with broad-spectrum activity in humans and animals.
 
2.  High Safety Profile in Approved Uses:
    •  Well-Tolerated: Ivermectin is generally safe at therapeutic doses, with mild side effects like nausea, dizziness, or rash occurring in <10% of patients. Serious adverse events (e.g., Mazzotti reaction in onchocerciasis) are rare and manageable.
    •  Wide Use in Global Health: Used safely in millions annually through WHO-led programs for neglected tropical diseases, including in children and pregnant women (after the first trimester).
 
3.  Potential Antiviral Effects (Investigational):
    •  In Vitro Activity: Studies show ivermectin inhibits viral replication in cell cultures for viruses like SARS-CoV-2, Zika, dengue, and HIV by blocking viral protein transport (e.g., via IMPα/β1 inhibition). However, effective concentrations in vitro (e.g., 5 µM for SARS-CoV-2) far exceed safe human plasma levels.
    •  COVID-19 (Controversial): Some small clinical studies and meta-analyses suggest potential benefits in reducing viral load, symptom duration, or mortality in COVID-19 patients, particularly in early treatment (e.g., 0.2–0.6 mg/kg for 1–5 days). However, major health authorities (WHO, FDA, NIH) state that evidence is insufficient due to inconsistent, low-quality trials, and ivermectin is not approved for COVID-19 treatment outside research settings.
 
4.  Anti-Inflammatory and Immunomodulatory Effects:
    •  Reduces Inflammation: Ivermectin may modulate immune responses by reducing pro-inflammatory cytokines (e.g., TNF-α, IL-6), potentially benefiting conditions like rosacea (topical use) or inflammatory parasitic diseases.
    •  Rosacea Treatment: Topical ivermectin (1% cream) is FDA-approved for inflammatory lesions of rosacea, reducing demodex mite density and inflammation with once-daily application.
5.  Potential Anticancer Effects (Emerging Research):
    •  In Vitro Studies: Ivermectin shows antiproliferative effects in cancer cell lines (e.g., breast, lung, colon) by inducing apoptosis, inhibiting cell cycle progression, and disrupting mitochondrial function. It may enhance chemotherapy efficacy (e.g., with paclitaxel).
    •  Limited Human Evidence: Anecdotal reports and preclinical data suggest potential, but no clinical trials confirm anticancer benefits in humans.